This observation is noteworthy as it suggests that mutant Cx43 (S368A) over‐expression is a useful delivery helper and collectively with CFZF‐VPR proves to be a novel means to deliver functional therapeutic zinc finger activators to treat CF patients (Figure 4). Here, GJA1 is linked to cystic fibrosis.